Business
OWC Pharmaceutical Research Corp. to Collaborate with Sourasky Medical Center in Tel Aviv for a Safety Study on Its Cannabis-Based Tablets
OWC Pharmaceutical Research Corp. to Collaborate with Sourasky Medical Center in Tel Aviv for a Safety Study on Its Cannabis-Based Tablets.
About this update from Owc Pharmaceutical Research Corp
[{"type":"text","content":"\n \n OWC \n Pharmaceutical Research Corp. (OTCQB: OWCP) (http://owcpharma.com/), \n the company transforming cannabis into scientifically proven and \n clinically approved medical solutions, announces an agreement with the \n Tel Aviv Sourasky Medical Center Fund.\n \n \n The medical center will perform a single-dose, randomized crossover \n study to compare the safety, tolerability, and pharmacokinetics of OWC’s \n tablet with Buccal Sativex in healthy adult volunteers. The tablet is \n designed to provide rapid API uptake through buccal membranes and to be \n a substitute for patients being treated with medical cannabis by smoking.\n \n \n OWC Pharmaceutical Research Corp. is focusing its efforts on developing \n cannabis-based therapeutic products and treatments, specifically \n designed for several medical conditions and diseases. The company’s \n solutions include a topical ointment to treat skin diseases, such as \n psoriasis, a sublingual disintegrating tablet to treat chronic pain, and \n a unique formulation aimed at treating multiple Myeloma, a cancer of the \n plasma cells found in bone marrow.\n \n \n “There is a very large amount of hype surrounding medical applications \n of cannabis, but we are one of the few companies doing real medical \n research,” says Mordechai Bignitz, CEO of OWC Pharmaceutical Research \n Corp. “Our collaboration with Sourasky Medical Center is further proof \n of our commitment to developing real cannabis-based medical solutions.”\n \n \n About OWC Pharmaceutical Research Corp.:OWC Pharmaceutical \n Research Corp. conducts medical research and clinical trials to develop \n cannabis-based pharmaceuticals and treatments for conditions including \n multiple myeloma, psoriasis, fibromyalgia, PTSD, and migraines. OWCP is \n also developing unique and effective delivery systems and dosage forms \n of medical cannabis.\n \n \n Notice Regarding Forward-Looking StatementsThis news \n release contains \"forward-looking statements\" as that term is defined in \n Section 27A of the United States Securities Act of 1933, as amended and \n Section 21E of the Securities Exchange Act of 1934, as amended. \n Statements in this press release, which are not purely historical, are \n forward-looking statements and include any statements regarding beliefs, \n plans, expectat...